Fig. 2. Effects of A1R antagonists on the hypnotic effect of β-Lap in pentobarbital-induced sleep in mice. The changes in (A) sleep onset latency and (B) total sleep time. β-Lap (1 mg/kg, p.o.) was administered to mice 30 min before pentobarbital injection (45 mg/kg, i.p.). DPCPX (5 mg/kg, p.o.), SCH (5 mg/kg, p.o.), FLU (5 mg/kg, p.o.), YNT (40 mg/kg, i.p.), DPAT (0.5 mg/kg, i.p.), LUZ (30 mg/kg, i.p.), or PEA (150 mg/kg, i.p.) was administered to mice 15 min before administration of β-Lap. Data are expressed as mean ± SEM (n=7-10). *p<0.05 vs CTL; **p<0.01 vs CTL; #p<0.05 vs VEH; ##p<0.01 vs VEH. CTL, control; VEH, vehicle; β-Lap, β-lapachone; DPCPX, 8-cyc lopentyl-1,3-dipropylxanthine; SCH, 2-(furan-2-yl)-7-phenethyl-7H-pyrazolo[4,3-e][1,2,4] triazolo[1,5-c]pyrimidin-5-amine; FLU, flumazenil; YNT, YNT-185 dihydrochloride; DPAT, 8-hydroxy-2-(di-n-propyl-amino) tetralin; LUZ, luzindole; PEA, 2-pyridineethan amine dihydrochloride; p.o., per oral; i.p., Intraperitoneal.
© Biomolecules & Therapeutics
